What do readers feel about these developments for women?
PromarkerD is indeed a blood test—but it’s not your everyday pathology panel. What makes it proprietary is the unique biomarker fingerprint and the cloud-based algorithm developed by Proteomics International Laboratories (ASX: PIQ) to predict diabetic kidney disease (DKD) years before symptoms appear.
Proteomics International (ASX: PIQ) isn’t just banking on PromarkerD—they’re building a suite of precision diagnostics under the Promarker® platform. Here's the full lineup:
PromarkerD – Diabetic Kidney Disease
- Type: Predictive blood test
- Purpose: Forecasts risk of developing DKD in type 2 diabetics up to 4 years in advance
- Status: Commercially launched in Australia; US rollout via CLIA lab underway
PromarkerEndo – Endometriosis
- Type: Diagnostic blood test
- Purpose: Detects endometriosis non-invasively, addressing a condition often diagnosed only via surgery
- Status: Expected to launch in Australia later in 2025
PromarkerEso – Esophageal Cancer
- Type: Diagnostic blood test
- Purpose: Aims to detect esophageal cancer earlier than current methods
- Status: Also slated for release in Australia before year-end
Platform Highlights
- Technology: All tests use PIQ’s proprietary proteomics approach—analyzing protein fingerprints in blood
- Cloud Integration: Results are processed via a secure algorithm to generate personalized risk or diagnostic reports
- Commercial Model: Direct-to-consumer (DTC) and healthcare referrals, with global expansion plans in motion
PIQ’s strategy is to replicate the digital infrastructure built for PromarkerD across its entire test portfolio. That means scalable deployment, faster market entry, and higher revenue retention compared to traditional licensing models.
